{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T10:35:19Z","timestamp":1789122919012,"version":"build-2803163510"},"reference-count":90,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.critrevonc.2021.103328","type":"journal-article","created":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T22:11:00Z","timestamp":1618956660000},"page":"103328","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"special_numbering":"C","title":["Chemotherapy for advanced gallbladder cancer (GBC): A systematic review and meta-analysis"],"prefix":"10.1016","volume":"163","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5216-1047","authenticated-orcid":false,"given":"Alexander A.","family":"Azizi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9696-6122","authenticated-orcid":false,"given":"Angela","family":"Lamarca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mair\u00e9ad G.","family":"McNamara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan W.","family":"Valle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2021.103328_bib0005","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.7314\/APJCP.2016.17.4.2137","article-title":"Radiological downstaging with neoadjuvant therapy in unresectable gall bladder cancer cases","volume":"17","author":"Agrawal","year":"2016","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.critrevonc.2021.103328_bib0010","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1385\/IJGC:32:2-3:107","article-title":"CPT-11 for bile-duct and gallbladder carcinoma: a phase II North Central Cancer Treatment Group (NCCTG) study","volume":"32","author":"Alberts","year":"2002","journal-title":"Int. J. Gastrointest. Cancer"},{"key":"10.1016\/j.critrevonc.2021.103328_bib0015","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/cncr.20753","article-title":"Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial","volume":"103","author":"Alberts","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2021.103328_bib0020","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s12029-008-9037-8","article-title":"Pemetrexed and gemcitabine for biliary tract and gallbladder carcinomas: a North Central Cancer Treatment Group (NCCTG) phase I and II Trial, N9943","volume":"38","author":"Alberts","year":"2007","journal-title":"J. Gastrointest. Cancer"},{"key":"10.1016\/j.critrevonc.2021.103328_bib0025","unstructured":"American Society of Clinical Oncology\u2019s Meeting Library (2019) [Online] [Accessed 14th April 2019]. Available from: https:\/\/meetinglibrary.asco.org\/."},{"key":"10.1016\/j.critrevonc.2021.103328_bib0030","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/sj.bjc.6604628","article-title":"Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study","volume":"99","author":"Andr\u00e9","year":"2008","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2021.103328_bib0035","doi-asserted-by":"crossref","first-page":"430","DOI":"10.4103\/0019-509X.176736","article-title":"Gallbladder cancer incidence in Gwalior district of India: five-year trend based on the registry of a regional cancer center","volume":"52","author":"Barbhuiya","year":"2015","journal-title":"Indian J. Cancer"},{"key":"10.1016\/j.critrevonc.2021.103328_bib0040","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41698-018-0064-z","article-title":"Emerging role of precision medicine in biliary tract cancers","volume":"2","author":"Bogenberger","year":"2018","journal-title":"NPJ Precis. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103328_bib0045","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.critrevonc.2021.103328_bib0050","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.ejca.2012.11.024","article-title":"Outcome of second-line chemotherapy for biliary tract cancer","volume":"49","author":"Bridgewater","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2021.103328_bib0055","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1002\/cncr.24970","article-title":"The cisplatin, epirubicin, 5-fluorouracil, gemcitabine (PEFG) regimen in advanced biliary tract adenocarcinoma","volume":"116","author":"Cereda","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2021.103328_bib0060","doi-asserted-by":"crossref","first-page":"526","DOI":"10.3349\/ymj.2005.46.4.526","article-title":"A phase II study of capecitabine combined with gemcitabine in patients with advanced gallbladder carcinoma","volume":"46","author":"Cho","year":"2005","journal-title":"Yonsei Med. J."},{"key":"10.1016\/j.critrevonc.2021.103328_bib0065","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1159\/000328021","article-title":"Prospective phase II trial of gemcitabine in combination with irinotecan as first-line chemotherapy in patients with advanced biliary tract cancer","volume":"57","author":"Chung","year":"2011","journal-title":"Chemotherapy"},{"key":"10.1016\/j.critrevonc.2021.103328_bib0070","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/jjco\/hyv148","article-title":"FOLFOX-4 as second-line therapy after failure of gemcitabine and platinum combination in advanced gall bladder cancer patients","volume":"46","author":"Dodagoudar","year":"2016","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103328_bib0075","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1038\/sj.bjc.6601736","article-title":"A Phase II study of gemcitabine and cisplatin in chemotherapy-naive, unresectable gall bladder cancer","volume":"90","author":"Doval","year":"2004","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2021.103328_bib0080","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1023\/A:1008241008379","article-title":"Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin","volume":"9","author":"Ducreux","year":"1998","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103328_bib0085","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/sj.bjc.6603648","article-title":"Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials","volume":"96","author":"Eckel","year":"2007","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2021.103328_bib0090","unstructured":"European Society of Medical Oncology\u2019s Meeting Resources (2019) [Online]. Available from: https:\/\/oncologypro.esmo.org\/Meeting-Resources (Accessed 14th April 2019)."},{"key":"10.1016\/j.critrevonc.2021.103328_bib0095","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/1097-0142(19840915)54:6<965::AID-CNCR2820540603>3.0.CO;2-X","article-title":"Eastern Cooperative Oncology Group experience with chemotherapy for inoperable gallbladder and bile duct cancer","volume":"54","author":"Falkson","year":"1984","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2021.103328_bib0100","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/01.coc.0000258124.72884.7a","article-title":"Irinotecan with 5-FU\/FA in advanced biliary tract adenocarcinomas: a multicenter phase II trial","volume":"30","author":"Feisthammel","year":"2007","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103328_bib0105","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/jjco\/hyl075","article-title":"Early phase II study of uracil-tegafur plus doxorubicin in patients with unresectable advanced biliary tract cancer","volume":"36","author":"Furuse","year":"2006","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103328_bib0110","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s00280-007-0673-7","article-title":"S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study","volume":"62","author":"Furuse","year":"2008","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.critrevonc.2021.103328_bib0115","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00280-009-1011-z","article-title":"A phase II study of uracil-tegafur plus doxorubicin and prognostic factors in patients with unresectable biliary tract cancer","volume":"65","author":"Furuse","year":"2009","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.critrevonc.2021.103328_bib0120","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1023\/A:1012543223020","article-title":"A phase II study of gemcitabine in gallbladder carcinoma","volume":"12","author":"Gallardo","year":"2001","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103328_bib0125","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s12029-015-9742-z","article-title":"Reduced dose intensity of chemotherapy may not lead to inferior palliation in locally advanced carcinoma of the gall bladder: an experience from a regional cancer centre in Eastern India","volume":"46","author":"Gangopadhyay","year":"2015","journal-title":"J. Gastrointest. Cancer"},{"key":"10.1016\/j.critrevonc.2021.103328_bib0130","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1002\/(SICI)1097-0142(19960915)78:6<1300::AID-CNCR19>3.0.CO;2-4","article-title":"Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.)","volume":"78","author":"Gebbia","year":"1996","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2021.103328_bib0135","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/j.1365-2559.2008.03192.x","article-title":"Gallbladder cancer: a morphological and molecular update","volume":"55","author":"Goldin","year":"2009","journal-title":"Histopathology"},{"key":"10.1016\/j.critrevonc.2021.103328_bib0140","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s00280-010-1351-8","article-title":"Fixed-dose-rate gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas","volume":"67","author":"Goldstein","year":"2011","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.critrevonc.2021.103328_bib0145","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1038\/sj.bjc.6603334","article-title":"Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer","volume":"95","author":"Harder","year":"2006","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2021.103328_bib0150","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00280-017-3341-6","article-title":"Prospective multicenter phase II study of gemcitabine plus cisplatin in patients with unresectable gallbladder cancer","volume":"80","author":"Hirooka","year":"2017","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.critrevonc.2021.103328_bib0155","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00280-006-0380-9","article-title":"Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer","volume":"60","author":"Hong","year":"2007","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.critrevonc.2021.103328_bib0160","first-page":"99","article-title":"Gallbladder cancer: epidemiology and outcome","volume":"6","author":"Hundal","year":"2014","journal-title":"Clin. Epidemiol."},{"key":"10.1016\/j.critrevonc.2021.103328_bib0165","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1093\/jjco\/hyu210","article-title":"Natural history of metastatic biliary tract cancer (BTC) patients with good performance status (PS) who were treated with only best supportive care (BSC)","volume":"45","author":"Ji","year":"2015","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103328_bib0170","first-page":"110","article-title":"A phase II study of gemcitabine and carboplatin combination chemotherapy in gallbladder carcinoma","volume":"5","author":"Julka","year":"2006","journal-title":"Hepatobiliary Pancreat. Dis. Int."},{"key":"10.1016\/j.critrevonc.2021.103328_bib0175","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1093\/annonc\/mdg281","article-title":"Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced biliary cancer","volume":"14","author":"Kim","year":"2003","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103328_bib0180","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/bjc.2011.17","article-title":"Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity","volume":"104","author":"Kim","year":"2011","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2021.103328_bib0185","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s00280-015-2687-x","article-title":"Phase II study of gemcitabine and S-1 combination chemotherapy in patients with metastatic biliary tract cancer","volume":"75","author":"Kim","year":"2015","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.critrevonc.2021.103328_bib0190","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s00280-017-3353-2","article-title":"Prognostic factors in patients with advanced biliary tract cancer treated with first-line gemcitabine plus cisplatin: retrospective analysis of 740 patients","volume":"80","author":"Kim","year":"2017","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.critrevonc.2021.103328_bib0195","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1200\/JCO.2005.51.008","article-title":"Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial","volume":"23","author":"Knox","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103328_bib0200","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/1471-2407-6-121","article-title":"A phase II study of LFP therapy (5-FU (5-fluorourasil) continuous infusion (CVI) and Low-dose consecutive (Cisplatin) CDDP) in advanced biliary tract carcinoma","volume":"6","author":"Kobayashi","year":"2006","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2021.103328_bib0205","author":"Lamarca","year":"2019","journal-title":"Presented at the American Society of Clinical Oncology, 2019-05-26"},{"key":"10.1016\/j.critrevonc.2021.103328_bib0210","doi-asserted-by":"crossref","DOI":"10.2174\/0929867327666200123090153","article-title":"Clinical and translational research challenges in biliary tract cancers","author":"Lamarca","year":"2020","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.critrevonc.2021.103328_bib0215","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jhep.2020.03.007","article-title":"Molecular targeted therapies: ready for \u201cprime time\u201d in biliary tract cancer","volume":"73","author":"Lamarca","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.critrevonc.2021.103328_bib0220","doi-asserted-by":"crossref","first-page":"4756","DOI":"10.2174\/0929867327666200123090153","article-title":"Clinical and translational research challenges in biliary tract cancers","volume":"27","author":"Lamarca","year":"2020","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.critrevonc.2021.103328_bib0225","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00280-007-0444-5","article-title":"Phase II trial of gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas","volume":"61","author":"Lee","year":"2008","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.critrevonc.2021.103328_bib0230","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.dld.2018.11.018","article-title":"Modified FOLFIRINOX versus CisGem first-line chemotherapy for locally advanced non resectable or metastatic biliary tract cancer (AMEBICA)-PRODIGE 38: study protocol for a randomized controlled multicenter phase II\/III study","volume":"51","author":"M.Phelip","year":"2019","journal-title":"Dig. Liver Dis."},{"key":"10.1016\/j.critrevonc.2021.103328_bib0235","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/01.COC.0000017090.36834.FE","article-title":"Prospective evaluation of efficacy and toxicity of 5-fu and folinic acid (Mayo Clinic regimen) in patients with advanced cancer of the gallbladder","volume":"26","author":"Malik","year":"2003","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103328_bib0240","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S1470-2045(14)70212-8","article-title":"Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial","volume":"15","author":"Malka","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2021.103328_bib0245","doi-asserted-by":"crossref","first-page":"61","DOI":"10.21037\/cco.2016.10.09","article-title":"Biliary tract cancers: epidemiology, molecular pathogenesis and genetic risk associations","volume":"5","author":"Marcano-Bonilla","year":"2016","journal-title":"Chin. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103328_bib0250","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1111\/cas.12218","article-title":"Randomized phase II study of gemcitabine plus S-1 versus S-1 in advanced biliary tract cancer: a Japan Clinical Oncology Group trial (JCOG 0805)","volume":"104","author":"Morizane","year":"2013","journal-title":"Cancer Sci."},{"key":"10.1016\/j.critrevonc.2021.103328_bib0255","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/1477-7819-11-117","article-title":"Prognostic predictive values of gemcitabine sensitivity-related gene products for unresectable or recurrent biliary tract cancer treated with gemcitabine alone","volume":"11","author":"Murata","year":"2013","journal-title":"World J. Surg. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103328_bib0260","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/sj.bjc.6604178","article-title":"Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial","volume":"98","author":"Nehls","year":"2008","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2021.103328_bib0265","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-018-4575-3","article-title":"Gallbladder cancer: review of a rare orphan gastrointestinal cancer with a focus on populations of New Mexico","volume":"18","author":"Nemunaitis","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2021.103328_bib0270","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/sj.bjc.6605779","article-title":"Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan","volume":"103","author":"Okusaka","year":"2010","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2021.103328_bib0275","article-title":"Gemcitabine and Cisplatin based combination chemotherapy in patients of locally advanced and metastatic gall bladder cancer","volume":"vol. 28","author":"Panda","year":"2017"},{"key":"10.1016\/j.critrevonc.2021.103328_bib0280","first-page":"3375","article-title":"Phase II trial of cisplatin, interferon alpha-2b, doxorubicin, and 5-fluorouracil for biliary tract cancer","volume":"7","author":"Patt","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2021.103328_bib0285","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1097\/CAD.0000000000000233","article-title":"Three-weekly oxaliplatin combined with gemcitabine and capecitabine in the first-line treatment of patients with advanced biliary tract cancer","volume":"26","author":"Petrioli","year":"2015","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.critrevonc.2021.103328_bib0290","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","article-title":"Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study","volume":"20","author":"Primrose","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2021.103328_bib0295","first-page":"71","article-title":"Effects of chemotherapy on patients with unresectable or metastatic adenocarcinoma of gallbladder","volume":"57","author":"Qayyum","year":"2007","journal-title":"J. Pak. Med. Assoc."},{"key":"10.1016\/j.critrevonc.2021.103328_bib0300","doi-asserted-by":"crossref","first-page":"5210","DOI":"10.3748\/wjg.14.5210","article-title":"Efficacy and safety of gemcitabine-oxaliplatin combined with huachansu in patients with advanced gallbladder carcinoma","volume":"14","author":"Qin","year":"2008","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.critrevonc.2021.103328_bib0305","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1002\/cncr.22902","article-title":"Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer","volume":"110","author":"Riechelmann","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2021.103328_bib0310","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1001\/jamaoncol.2019.0269","article-title":"Gemcitabine, cisplatin, and nab-paclitaxel for patients with advanced biliary tract cancer: closing the GAP","volume":"5","author":"Roth","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2021.103328_bib0315","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1159\/000329079","article-title":"A phase II trial of fixed-dose rate gemcitabine plus capecitabine in metastatic\/advanced biliary tract cancer patients","volume":"82","author":"Santini","year":"2012","journal-title":"Oncology"},{"key":"10.1016\/j.critrevonc.2021.103328_bib0320","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1007\/s10637-010-9553-9","article-title":"Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine","volume":"30","author":"Sasaki","year":"2012","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.critrevonc.2021.103328_bib0325","doi-asserted-by":"crossref","first-page":"4581","DOI":"10.1200\/JCO.2010.29.3605","article-title":"Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study","volume":"28","author":"Sharma","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103328_bib0330","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s00280-009-1055-0","article-title":"A phase II study of gemcitabine and oxaliplatin (Oxigem) in unresectable gall bladder cancer","volume":"65","author":"Sharma","year":"2010","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.critrevonc.2021.103328_bib0335","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.4077","article-title":"Final results of a phase III randomized controlled trial comparing modified gemcitabine + oxaliplatin (mGEMOX) to gemcitabine+ cisplatin in management of unresectable gall bladder cancer (GBC)","volume":"34","author":"Sharma","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103328_bib0340","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ejca.2019.10.004","article-title":"Modified gemcitabine and oxaliplatin or gemcitabine + cisplatin in unresectable gallbladder cancer: results of a phase III randomised controlled trial","volume":"123","author":"Sharma","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2021.103328_bib0345","first-page":"2708","article-title":"Evaluation of systemic chemotherapy for unresectable gallbladder carcinoma","volume":"37","author":"Shimizu","year":"2010","journal-title":"Gan To Kagaku Ryoho"},{"key":"10.1016\/j.critrevonc.2021.103328_bib0350","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.18.02178","article-title":"Adjuvant therapy for resected biliary tract cancer: ASCO clinical practice guideline","author":"Shroff","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103328_bib0355","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1001\/jamaoncol.2019.0270","article-title":"Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: a phase 2 clinical trial","volume":"5","author":"Shroff","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2021.103328_bib0360","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s10555-016-9602-8","article-title":"Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design","volume":"35","author":"Sicklick","year":"2016","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.critrevonc.2021.103328_bib0365","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s13193-015-0443-7","article-title":"Chemotherapy compared with best supportive care for metastatic\/unresectable gallbladder cancer: a non-randomized prospective cohort study","volume":"7","author":"Singh","year":"2016","journal-title":"Indian J. Surg. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103328_bib0370","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s12029-017-9940-y","article-title":"Patterns of presentation, treatment, and survival rates of gallbladder cancer: a prospective study at a tertiary care centre","volume":"49","author":"Singh","year":"2018","journal-title":"J. Gastrointest. Cancer"},{"key":"10.1016\/j.critrevonc.2021.103328_bib0375","first-page":"207","article-title":"NAB-PACLITAXEL as third-line therapy after failure of Gemcitabine and 5-FU based combinations in advanced gall bladder cancer patients","volume":"vol. 27","author":"Singh Manana","year":"2016"},{"key":"10.1016\/j.critrevonc.2021.103328_bib0380","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1177\/030089161309900203","article-title":"Phase II trial of combination chemotherapy with gemcitabine, 5-fluorouracil and cisplatin for advanced cancers of the bile duct, gallbladder, and ampulla of Vater","volume":"99","author":"Sohn","year":"2013","journal-title":"Tumori"},{"key":"10.1016\/j.critrevonc.2021.103328_bib0385","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1159\/000318020","article-title":"Treatment efficacy\/safety and prognostic factors in patients with advanced biliary tract cancer receiving gemcitabine monotherapy: an analysis of 100 cases","volume":"79","author":"Suzuki","year":"2010","journal-title":"Oncology"},{"key":"10.1016\/j.critrevonc.2021.103328_bib0390","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s00280-013-2106-0","article-title":"A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer","volume":"71","author":"Suzuki","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.critrevonc.2021.103328_bib0395","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1023\/B:DRUG.0000011797.09549.53","article-title":"Weekly gemcitabine for the treatment of biliary tract and gallbladder cancer","volume":"22","author":"Tsavaris","year":"2004","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.critrevonc.2021.103328_bib0400","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1038\/sj.bjc.6602208","article-title":"Phase II study of S-1 in patients with advanced biliary tract cancer","volume":"91","author":"Ueno","year":"2004","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2021.103328_bib0405","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2021.103328_bib0410","doi-asserted-by":"crossref","first-page":"v28","DOI":"10.1093\/annonc\/mdw324","article-title":"Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Valle","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2021.103328_bib0415","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1158\/2159-8290.CD-17-0245","article-title":"New horizons for precision medicine in biliary tract cancers","volume":"7","author":"Valle","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2021.103328_bib0420","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1038\/sj.bjc.6605377","article-title":"Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trials","volume":"101","author":"Wagner","year":"2009","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2021.103328_bib0425","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ejca.2012.08.003","article-title":"Feasibility and benefits of second-line chemotherapy in advanced biliary tract cancer: a large retrospective study","volume":"49","author":"Walter","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2021.103328_bib0430","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1056\/NEJMe1001183","article-title":"A step forward in the treatment of advanced biliary tract cancer","volume":"362","author":"Wolpin","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2021.103328_bib0435","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1159\/000339499","article-title":"Capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective single-center study","volume":"58","author":"Woo","year":"2012","journal-title":"Chemotherapy"},{"key":"10.1016\/j.critrevonc.2021.103328_bib0440","doi-asserted-by":"crossref","first-page":"594","DOI":"10.5009\/gnl.2013.7.5.594","article-title":"A multicenter phase II trial of gemcitabine plus oxaliplatin in unresectable gallbladder cancer","volume":"7","author":"Woo","year":"2013","journal-title":"Gut Liver"},{"key":"10.1016\/j.critrevonc.2021.103328_bib0445","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.4143\/crt.2017.526","article-title":"Multicenter phase II study of oxaliplatin, irinotecan, and S-1 as first-line treatment for patients with recurrent or metastatic biliary tract cancer","volume":"50","author":"Yoo","year":"2018","journal-title":"Cancer Res. Treat."},{"key":"10.1016\/j.critrevonc.2021.103328_bib0450","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12885-018-5211-y","article-title":"Therapeutic outcomes and prognostic factors in unresectable gallbladder cancer treated with gemcitabine plus cisplatin","volume":"19","author":"You","year":"2019","journal-title":"BMC Cancer"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842821001165?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842821001165?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:38:29Z","timestamp":1760902709000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842821001165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":90,"alternative-id":["S1040842821001165"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2021.103328","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chemotherapy for advanced gallbladder cancer (GBC): A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2021.103328","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103328"}}